Tirzepatide has dominated metabolic health headlines worldwide in 2026, with this dual GLP-1/GIP receptor agonist delivering 22–27 % sustained body-weight loss in real-world registries — far surpassing every previous therapy including Semaglutide. The newly launched oral Tirzepatide tablet eliminates needles while retaining 94 % of the injectable’s power, achieving 18–23 % reduction in landmark trials. […]